Comparative Pharmacology
Head-to-head clinical analysis: ADAPALENE versus SORIATANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADAPALENE versus SORIATANE.
ADAPALENE vs SORIATANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoic acid receptor agonist; binds to RARβ/γ nuclear receptors, modulating gene expression to normalize follicular keratinization and reduce comedogenesis.
Retinoid that binds to nuclear retinoic acid receptors (RARs), modulating gene expression involved in cell proliferation, differentiation, and apoptosis.
Apply a pea-sized amount topically to affected areas once daily in the evening.
Initial: 25-50 mg orally once daily; maintenance: 25-50 mg orally once daily; not to exceed 75 mg/day.
None Documented
None Documented
The terminal elimination half-life of adapalene after topical application is approximately 17 hours (range 7–51 hours), reflecting slow release from skin depot and hepatic clearance. This supports once-daily dosing.
Clinical Note
moderateAdapalene + Gatifloxacin
"Adapalene may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateAdapalene + Rosoxacin
"Adapalene may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateAdapalene + Levofloxacin
"Adapalene may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateAdapalene + Trovafloxacin
"Adapalene may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life of etretinate (active form) is ≈100–125 days due to storage in adipose tissue; clinically relevant for prolonged teratogenicity.
Adapalene is eliminated primarily via biliary excretion into feces. After oral administration in animals, approximately 80% of the dose is recovered in feces and about 10% in urine; for topical application, systemic absorption is minimal and the small absorbed fraction undergoes similar hepatobiliary elimination.
Primarily hepatic metabolism; eliminated via feces (≈60%) and urine (≈15%) as metabolites; parent drug not excreted unchanged.
Category D/X
Category C
Retinoid
Retinoid